ZA200001593B - Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [B,E] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization. - Google Patents

Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [B,E] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization.

Info

Publication number
ZA200001593B
ZA200001593B ZA200001593A ZA200001593A ZA200001593B ZA 200001593 B ZA200001593 B ZA 200001593B ZA 200001593 A ZA200001593 A ZA 200001593A ZA 200001593 A ZA200001593 A ZA 200001593A ZA 200001593 B ZA200001593 B ZA 200001593B
Authority
ZA
South Africa
Prior art keywords
dimethylaminopropylidene
dihydrodibenz
oxepin
medicament
prevention
Prior art date
Application number
ZA200001593A
Other languages
English (en)
Inventor
John M Yani
Daniel A Gamache
Lori K Weimer
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of ZA200001593B publication Critical patent/ZA200001593B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200001593A 1998-07-14 2000-03-29 Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [B,E] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization. ZA200001593B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9276298P 1998-07-14 1998-07-14

Publications (1)

Publication Number Publication Date
ZA200001593B true ZA200001593B (en) 2000-10-25

Family

ID=22235027

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200001593A ZA200001593B (en) 1998-07-14 2000-03-29 Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [B,E] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization.

Country Status (18)

Country Link
EP (1) EP1037627B1 (es)
JP (1) JP2002520355A (es)
KR (1) KR100598723B1 (es)
CN (1) CN1114401C (es)
AR (1) AR019916A1 (es)
AT (1) ATE203668T1 (es)
AU (1) AU742237B2 (es)
BR (1) BR9906772A (es)
CA (1) CA2306393C (es)
DE (1) DE69900207T2 (es)
DK (1) DK1037627T3 (es)
ES (1) ES2159209T3 (es)
GR (1) GR3036422T3 (es)
HK (1) HK1030362A1 (es)
PT (1) PT1037627E (es)
TW (1) TW561046B (es)
WO (1) WO2000003705A1 (es)
ZA (1) ZA200001593B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2374002A1 (en) * 1999-06-18 2000-12-28 Alcon Laboratories, Inc. Topical ophthalmic mast cell stabilizers for treating allergic eye diseases
AU2002224337A1 (en) * 2000-10-23 2002-05-06 Alcon, Inc. Use of hydroperoxyeicosatetraenoic acid derivatives following refractive surgery
CN1509462A (zh) 2001-05-21 2004-06-30 NF-κB抑制剂在治疗干眼疾病中的用途
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
PL367287A1 (en) 2001-05-21 2005-02-21 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US6645994B1 (en) 2001-06-01 2003-11-11 Alcon, Inc. Method of treating dry eye disorders
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
WO2003105831A1 (en) * 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
CN101327325A (zh) * 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
US7026296B2 (en) 2002-09-20 2006-04-11 Alcon, Inc. Methods of treating dry eye disorders
US7235556B2 (en) 2003-04-16 2007-06-26 Alcon, Inc. Methods of treating dry eye disorders
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US7923471B2 (en) 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US7223737B1 (en) 2004-08-13 2007-05-29 Alcon, Inc. Method of treating dry eye disorders using glycosides
PL2444079T3 (pl) * 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
US7745461B1 (en) 2006-02-27 2010-06-29 Alcon Research, Ltd. Method of treating dry eye disorders
KR20150017002A (ko) 2006-03-17 2015-02-13 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 눈용 조성물
WO2007115261A2 (en) 2006-03-31 2007-10-11 Qlt Plug Delivery, Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
AU2008300022A1 (en) 2007-09-07 2009-03-19 Qlt Inc. Lacrimal implant detection
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
AU2010314956A1 (en) 2009-11-06 2012-04-12 Alcon Research, Ltd. Nutritional supplements for relief of dry eye
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
EP3472203A1 (en) 2016-06-20 2019-04-24 Novartis AG Methods of treating dry eye disease using tnf alpha antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
JPH02138215A (ja) * 1988-08-05 1990-05-28 Dai Ichi Seiyaku Co Ltd 抗アレルギー・抗炎症剤
IE920499A1 (en) * 1991-02-21 1992-08-26 Merck Frosst Canada Inc Quinoline-containing ketoacids as leukotriene antagonists
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
JP3453152B2 (ja) * 1992-04-06 2003-10-06 格 冨山 抗炎症点眼剤
FR2701948B1 (fr) * 1993-02-22 1996-07-26 Exsymol Sa Produit de couplage de l'histamine ou l'histamine méthyl-substituée et d'un acide aminé, procédé de préparation et applications thérapeutiques, cosmétologiques et agroalimentaires.
WO1994022448A1 (en) * 1993-03-26 1994-10-13 Beth Israel Hospital Association Topical and systemic application of buspirone or derivatives thereof for treatment of pathological conditions associated with immune responses
FR2711990B1 (fr) * 1993-11-05 1995-12-08 Exsymol Sa Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires.
JP2852607B2 (ja) * 1994-06-10 1999-02-03 雪印乳業株式会社 ドライアイ治療剤
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
JPH1067684A (ja) * 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
WO1998022130A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye

Also Published As

Publication number Publication date
CN1275078A (zh) 2000-11-29
DE69900207D1 (de) 2001-09-06
CN1114401C (zh) 2003-07-16
DE69900207T2 (de) 2001-11-22
CA2306393A1 (en) 2000-01-27
BR9906772A (pt) 2000-09-26
AU4563499A (en) 2000-02-07
EP1037627A1 (en) 2000-09-27
AU742237B2 (en) 2001-12-20
AR019916A1 (es) 2002-03-27
DK1037627T3 (da) 2001-10-01
PT1037627E (pt) 2001-11-30
HK1030362A1 (en) 2001-05-04
KR20010024508A (ko) 2001-03-26
TW561046B (en) 2003-11-11
ES2159209T3 (es) 2001-09-16
ATE203668T1 (de) 2001-08-15
CA2306393C (en) 2008-12-23
EP1037627B1 (en) 2001-08-01
GR3036422T3 (en) 2001-11-30
WO2000003705A1 (en) 2000-01-27
JP2002520355A (ja) 2002-07-09
KR100598723B1 (ko) 2006-07-11

Similar Documents

Publication Publication Date Title
ZA200001593B (en) Use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz [B,E] oxepin-2-acetic acid for the manufacture of a medicament for treating non-allergic ophthalmic inflammatory disorders and for the prevention of ocular neovascularization.
HK1085647A1 (en) Benzo [d]azepine derivatives for the treatment of neurological disorders
EP1100508B8 (en) Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
MY116651A (en) Topical ophthalmic formulations for treating allergic eye diseases
HUP0000576A3 (en) Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts
IL153425A0 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
PL352229A1 (en) Prosthesis of sclera for treatment of presbyopia and other sight disorders
HK1023293A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
WO2001098279A3 (en) Bis-arylsulfones
EP1440689A3 (en) Treatment of neurotic disorders
NO20013645L (no) Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjon av de perifere benzodiazepinreseptorer
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
EP1126850A4 (en) TREATMENT OF CONDITIONS OF THE RETINA
GB9926968D0 (en) Treatment of neurological disorders
AU5912900A (en) Quinuclidine derivatives for treatment of neurological disorders
WO2002043715A3 (de) Verwendung von 1-phenyl-3-dimethylamino-propanverbindungen zur therapie der harninkontinenz
AU6386700A (en) Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
HK1047695A1 (en) Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina
CA2260863A1 (en) Treatment of psychotic disorders
MXPA01003761A (es) Agente para tratar oftalmopatia.
AU4026501A (en) Prolate shaped corneal reshaping
WO2002043714A3 (de) Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
WO2002043712A3 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz
IL149669A0 (en) NEW THERAPEUTIC COMBINATIONS OF (S) -2-(BENZYLAMINO-METHYL)-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e] INDOL-8-ONE AND NEUROLEPTICS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS